Identification of AML1-ETO modulators by chemical genomics

Blood

Volumn 113, Issue 24, 2009, Pages 6193-6205

  Corsello, Steven M ^a   Roti, Giovanni ^a   Ross, Kenneth N ^b   Chow, Kwan T ^a   Galinsky, Ilene ^a   DeAngelo, Daniel J ^a   Stone, Richard M ^a   Kung, Andrew L ^a   Golub, Todd R ^a,b,c   Stegmaier, Kimberly ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AML1 ETO FUSION PROTEIN; BETA ACTIN; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLINIC ACID; GLUCOCORTICOID RECEPTOR; HYBRID PROTEIN; METHOTREXATE; METHYLPREDNISOLONE; MIFEPRISTONE; PROTEASOME; PROTEIN INHIBITOR; PYRIMETHAMINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DRUG; HISTONE; HISTONE DEACETYLASE; MESSENGER RNA; ONCOPROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER MODEL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENOMICS; HUMAN; HUMAN CELL; MALE; MOLECULAR LIBRARY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; ACETYLATION; ANIMAL; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; COMBINATORIAL CHEMISTRY; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOBLOTTING; METABOLISM; NEOPLASM; NONOBESE DIABETIC MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COMBINATORIAL CHEMISTRY TECHNIQUES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENOMICS; HISTONE DEACETYLASES; HISTONES; HUMANS; IMMUNOBLOTTING; MALE; MICE; MICE, INBRED NOD; MYELOID CELLS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PHARMACEUTICAL PREPARATIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSLOCATION, GENETIC;

EID: 67650379749     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-166090     Document Type: Article

References (43)

1. Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nat Genet. 2004;36:257-263.
2. Peck D, Crawford ED, Ross KN, Stegmaier K, Golub TR, Lamb J. A method for high-throughput gene expression signature analysis. Genome Biol. 2006;7:R61.
3. Bitter MA, Le Beau MM, Rowley JD, Larson RA, Golomb HM, Vardiman JW. Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum Pathol. 1987;18:211-225.
4. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991;88:10431-10434.
5. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992;80:1825-1831.
6. Erickson PF, Robinson M, Owens G, Drabkin HA. The ETO portion of acute myeloid leukemia t(8; 21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. Cancer Res. 1994;54:1782-1786. (Pubitemid 24116186)
7. Shimizu K, Miyoshi H, Kozu T, et al. Consistent disruption of the AML1 gene occurs within a single intron in the t(8;21) chromosomal translocation. Cancer Res. 1992;52:6945-6948. (Pubitemid 23006304)
8. Lutterbach B, Westendorf JJ, Linggi B, et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol. 1998;18:7176-7184.
9. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18:7185-7191. (Pubitemid 28533038)
10. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A. 1998;95:10860-10865. (Pubitemid 28413159)
11. Okuda T, Cai Z, Yang S, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 1998;91:3134-3143. (Pubitemid 28193861)
12. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1:63-74. (Pubitemid 41039177)
13. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1- ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 2002;99: 15-23.
14. Mulloy JC, Cammenga J, Berguido FJ, et al. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood. 2003;102: 4369-4376. (Pubitemid 37494097)
15. Tonks A, Tonks AJ, Pearn L, et al. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia. 2004;18: 1238-1245. (Pubitemid 39023134)
16. Sakakura C, Yamaguchi-Iwai Y, Satake M, et al. Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/ MTG8(ETO)-specific antisense oligonucleotide. Proc Natl Acad Sci U S A. 1994;91:11723-11727.
17. Heidenreich O, Krauter J, Riehle H, et al. AML1/ MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)- positive leukemic cells. Blood. 2003;101:3157-3163. (Pubitemid 36858010)
18. Martinez N, Drescher B, Riehle H, et al. The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8; 21)-positive leukaemic cells. BMC Cancer. 2004; 4:44. (Pubitemid 40180242)
19. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
20. Pabst T, Mueller BU, Harakawa N, et al. AML1- ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med. 2001;7:444-451. (Pubitemid 32298547)
21. Gessner PK. Isobolographic analysis of interactions: an update on applications and utility. Toxicology. 1995;105:161-179.
22. Kimbrel EA, Davis TN, Bradner JE, Kung AL. In vivo pharmacodynamic imaging of proteasome inhibition. Mol Imaging. In press.
23. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173-183.
24. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617-1628. (Pubitemid 38528701)
25. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-15550. (Pubitemid 41528093)
26. Krämer OH, Müller S, Buchwald M, Reichardt S, Heinzel T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RAR α. FASEB J. 2008;22:1369-1379. (Pubitemid 351656778)
27. Mao X, Stewart AK, Hurren R, et al. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood. 2007;110:4047-4054. (Pubitemid 350248461)
28. Yang G, Thompson MA, Brandt SJ, Hiebert SW. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene. 2007;26:91-101. (Pubitemid 46067334)
29. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
30. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-1320.
31. Miyoshi H, Ohki M, Nakagawa T, Honma Y. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with A t(8;21) chromosome translocation. Leuk Res. 1997;21:45-50. (Pubitemid 27073241)
32. Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SD. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene. 1999;18:1701-1710. (Pubitemid 29137461)
33. Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990;62:1189-1204. (Pubitemid 20333778)
34. Shimohakamada Y, Shinohara K, Fukuda N. Remission of acute myeloblastic leukemia after severe pneumonia treated with high-dose methylprednisolone. Int J Hematol. 2001;74:173-177. (Pubitemid 33760068)
35. Muller CI, Trepel M, Kunzmann R, Lais A, Engelhardt R, Lubbert M. Hematologic and molecular spontaneous remission following sepsis in acute monoblastic leukemia with translocation (9;11): a case report and review of the literature. Eur J Haematol. 2004;73:62-66. (Pubitemid 38824192)
36. Hicsonmez G, Cetin M, Aslan D, Ozyurek E. The role of short course of high-dose methylprednisolone in children with acute myeloblastic leukemia (FAB M2) presented with myeloid tumor. Pediatr Hematol Oncol. 2003;20:373-379. (Pubitemid 36869793)
37. Rubnitz JE, Raimondi SC, Halbert AR, et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience. Leukemia. 2002;16:2072-2077.
38. Argiris A, Longo GS, Gorlick R, Tong W, Steinherz P, Bertino JR. Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia. Leukemia. 1997;11:886-889.
39. Göker E, Kheradpour A, Waltham M, et al. Acute monocytic leukemia: a myeloid leukemia subset that may be sensitive to methotrexate. Leukemia. 1995;9:274-276.
40. Peeters M, Poon A. Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr. 1987;146: 416-422. (Pubitemid 17130864)
41. Rots MG, Pieters R, Jansen G, et al. A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia. Eur J Cancer. 2001; 37:492-498.
42. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310:644-648. (Pubitemid 41528150)
43. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448:595-599. (Pubitemid 47206938)